GAITHERSBURG, Md., May 14, 2021 /PRNewswire/ -- MaxCyte, Inc.
(LSE: MXCT, MXCL, MXCN) ("MaxCyte" or the "Company"),
a leading provider of platform technologies for cell engineering,
today announces that it has confidentially submitted a draft
registration statement on Form S-1 with the Securities and Exchange
Commission (the "SEC") relating to a proposed dual-listing
and public offering of shares of common stock on the Nasdaq Stock
Market (the "Offering").
The number of securities to be offered and the price for the
proposed Offering have not yet been determined. The Offering
is expected to commence after the SEC completes its review process,
subject to market and other conditions, and shareholders and
potential investors should note that the proposed Offering may or
may not proceed.
This press release is being made pursuant to, and in accordance
with, Rule 135 under the Securities Act of 1933, as amended (the
"Securities Act"). This press release does not
constitute an offer to sell or the solicitation of an offer to buy
securities, and shall not constitute an offer, solicitation or sale
in any jurisdiction in which such offer, solicitation or sale would
be unlawful prior to registration or qualification under the
securities laws of that jurisdiction. Any offers, solicitations or
offers to buy, or any sales of securities will be made in
accordance with the registration requirements of the Securities
Act.
About MaxCyte
MaxCyte is a leading commercial
cell-engineering company focused on providing enabling platform
technologies to advance innovative cell-based research as well as
next-generation cell therapeutic discovery, development and
commercialization. MaxCyte's existing customer base ranges from
large biopharmaceutical companies, including all of the top 10, and
20 of the top 25, pharmaceutical companies based on 2020 global
revenue, to hundreds of biotechnology companies and academic
centers focused on translational research. MaxCyte has granted 12
strategic platform licences to commercial cell therapy developers.
Including these strategic platform licences, MaxCyte has granted
research and clinical licences with academic and industry customers
covering over an estimated 140 programs, and clinical licences with
academic and industry customers covering over an estimated 100
programs being developed for use in humans. MaxCyte was founded in
1998 and is headquartered in Gaithersburg, Maryland, US.
The person responsible for arranging the release of this
announcement on behalf of the Company is Doug Doerfler, President and Chief Executive
Officer of MaxCyte, Inc.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/proposed-dual-listing-on-nasdaq-301291473.html
SOURCE MaxCyte, Inc.